Another post by Joe... I would say this is the
Post# of 36537
I would say this is the most important thing to ask any company doing a vaccine for covid 19
Question as it relates to The hunt for an effective Antibody and Cellular responsive (long term memory) Vaccine for COVID 19.
There are many companies in this hunt using 4 primary pathways to Deliver Antibody with the hope of a Cellular response, but will they work, is the question.
A lot of hope out there for these pathways but here are my facts as I see them, unless someone knows something I don’t and or can provide feed back, which would be much appreciated,
Pathways:
RNA - not a single drug has ever made it through the clinic and or gotten commercialized to date, and the potential for very bad off target events, I have also not seen any with significant, positive data with big benefit - have you?
DNA - Since the human Genome program has completed its quest to decipher the human quest for life, again nothing has ever been commercialized in the Vaccine area that has even been close to significance or positive benefiting results.
Cell Clamping - well I’m not even sure this pathway is worth talking about, just to many failures to even sought through, again with zero results.
mRNA - Another area pretty short on intermediate positive benefiting results, very high risk in off target events, and zero commercialization results.
So all these companies with all these prior failures some how, some way, figured out, finally how to use these pathways to protect against COVID 19, that to me is either a lot of hope and hope mongering or just simply opportunity, I quest we will see.
So my big question to these 4 pathways companies, so what has changed, what has made your pathway NOW so super, that you now believe with all the mountains of failures behind you and no data to speak of you believe FINALLY you figured out some new way of deploying these pathways to help people and protect them, I really wonder!
Would appreciate any input I may of missed! I hope I’m wrong!
https://www.nejm.org/doi/full/10.1056/NEJMp2005630